The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Ongoing trials in amyloidosis
Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of the current clinical trials underway researching treatment methods of amyloidosis. Dr Dispenzieri discusses a re-emerging therapeutic strategy, amyloid-targeted antibodies, which was previously discontinued due to a lack of benefit from agents such as birtamimab (NEOD001). Dr Dispenzieri also talks of ongoing trials investigating BCL-2 inhibition in the refractory setting for light-chain amyloidosis and discusses the prospects of antibody-drug conjugates, a treatment method which is increasingly gaining attention. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
